Regencell Bioscience Holdings Limited (RGC)

NASDAQ: RGC · IEX Real-Time Price · USD
4.500
+1.100 (32.35%)
At close: Mar 28, 2024, 3:59 PM
4.300
-0.200 (-4.44%)
After-hours: Mar 28, 2024, 7:57 PM EDT

Company Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.

It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases.

The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings logo
Country Hong Kong
Founded 2014
IPO Date Jul 16, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 12
CEO Yat-Gai Au

Contact Details

Address:
11/f First Commercial Building, 33-35 Leighton Road, Causeway Bay
Hong Kong, K3 999077
Hong Kong
Phone 852 2155 0823
Website regencellbioscience.com

Stock Details

Ticker Symbol RGC
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
IPO Price $9.50
CIK Code 0001829667
CUSIP Number G7487R100
ISIN Number KYG7487R1002
SIC Code 2833

Key Executives

Name Position
Yat-Gai Au Founder, Chairman and Chief Executive Officer
Michelle Chan Financial Controller
Wai Hong Chung Chief Operating Officer and Chief Strategy Officer
Dr. Yi-Chung Chao Ph.D. Special Advisor and Director
Tien Hsiang Chau Executive Officer
Antonia Assang Senior Vice President of Project Management
Yat-Pui Au Chief Business Officer

Latest SEC Filings

Date Type Title
Jan 2, 2024 6-K Report of foreign issuer
Dec 15, 2023 6-K Report of foreign issuer
Oct 27, 2023 20-F Annual and transition report of foreign private issuers
Jun 15, 2023 6-K Report of foreign issuer
Jun 5, 2023 6-K Report of foreign issuer
Mar 17, 2023 6-K Report of foreign issuer
Feb 28, 2023 6-K Report of foreign issuer
Jan 4, 2023 6-K Report of foreign issuer
Dec 22, 2022 6-K Report of foreign issuer
Oct 31, 2022 20-F Annual and transition report of foreign private issuers